WO2021259334A1 - Self-regulating chimeric antigen receptor and application thereof in tumor immunity - Google Patents
Self-regulating chimeric antigen receptor and application thereof in tumor immunity Download PDFInfo
- Publication number
- WO2021259334A1 WO2021259334A1 PCT/CN2021/101900 CN2021101900W WO2021259334A1 WO 2021259334 A1 WO2021259334 A1 WO 2021259334A1 CN 2021101900 W CN2021101900 W CN 2021101900W WO 2021259334 A1 WO2021259334 A1 WO 2021259334A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- cells
- car
- tumor
- nucleotide sequence
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 127
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 112
- 230000036039 immunity Effects 0.000 title abstract description 4
- 230000014509 gene expression Effects 0.000 claims abstract description 155
- 239000000427 antigen Substances 0.000 claims abstract description 126
- 108091007433 antigens Proteins 0.000 claims abstract description 126
- 102000036639 antigens Human genes 0.000 claims abstract description 126
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 74
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 57
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 51
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 51
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 34
- 102000004127 Cytokines Human genes 0.000 claims abstract description 12
- 108090000695 Cytokines Proteins 0.000 claims abstract description 12
- 239000003446 ligand Substances 0.000 claims abstract description 8
- 108020003175 receptors Proteins 0.000 claims abstract description 7
- 102000005962 receptors Human genes 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 232
- 239000013612 plasmid Substances 0.000 claims description 149
- 239000002773 nucleotide Substances 0.000 claims description 92
- 125000003729 nucleotide group Chemical group 0.000 claims description 92
- 239000003623 enhancer Substances 0.000 claims description 82
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 74
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 61
- 108091027981 Response element Proteins 0.000 claims description 45
- 241000700605 Viruses Species 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 37
- 108010002350 Interleukin-2 Proteins 0.000 claims description 36
- 102000000588 Interleukin-2 Human genes 0.000 claims description 35
- 239000013598 vector Substances 0.000 claims description 34
- 108700026226 TATA Box Proteins 0.000 claims description 33
- 238000010361 transduction Methods 0.000 claims description 26
- 230000026683 transduction Effects 0.000 claims description 26
- 239000013603 viral vector Substances 0.000 claims description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 102000003945 NF-kappa B Human genes 0.000 claims description 14
- 108010057466 NF-kappa B Proteins 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 14
- 238000004806 packaging method and process Methods 0.000 claims description 14
- 108020004414 DNA Proteins 0.000 claims description 13
- 102000040945 Transcription factor Human genes 0.000 claims description 12
- 108091023040 Transcription factor Proteins 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 230000001177 retroviral effect Effects 0.000 claims description 11
- 210000004881 tumor cell Anatomy 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000010276 construction Methods 0.000 claims description 8
- 239000003999 initiator Substances 0.000 claims description 8
- 230000019491 signal transduction Effects 0.000 claims description 8
- 206010021143 Hypoxia Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 101150046266 foxo gene Proteins 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 230000007954 hypoxia Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 230000002441 reversible effect Effects 0.000 claims description 6
- 241000702421 Dependoparvovirus Species 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 102000009410 Chemokine receptor Human genes 0.000 claims description 4
- 108050000299 Chemokine receptor Proteins 0.000 claims description 4
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims description 4
- 108091026908 Downstream promoter element Proteins 0.000 claims description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 240000007019 Oxalis corniculata Species 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000017105 transposition Effects 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 102000000479 TCF Transcription Factors Human genes 0.000 claims description 3
- 108010016283 TCF Transcription Factors Proteins 0.000 claims description 3
- 102000004408 Transcription factor TFIIB Human genes 0.000 claims description 3
- 108090000941 Transcription factor TFIIB Proteins 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 210000002865 immune cell Anatomy 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 2
- 102000002227 Interferon Type I Human genes 0.000 claims description 2
- 108010014726 Interferon Type I Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 abstract description 64
- 230000000694 effects Effects 0.000 abstract description 22
- 239000012636 effector Substances 0.000 abstract description 9
- 230000003213 activating effect Effects 0.000 abstract description 5
- 230000009885 systemic effect Effects 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 82
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 65
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 65
- 230000000638 stimulation Effects 0.000 description 32
- 239000002609 medium Substances 0.000 description 31
- 108091008874 T cell receptors Proteins 0.000 description 27
- 238000000684 flow cytometry Methods 0.000 description 26
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 24
- 239000006228 supernatant Substances 0.000 description 22
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 21
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 21
- 230000037361 pathway Effects 0.000 description 21
- 241000713666 Lentivirus Species 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 19
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 19
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 19
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 19
- 230000033228 biological regulation Effects 0.000 description 18
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 18
- 230000035897 transcription Effects 0.000 description 18
- 238000013518 transcription Methods 0.000 description 18
- 102100039641 Protein MFI Human genes 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 15
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 210000004989 spleen cell Anatomy 0.000 description 15
- 230000006698 induction Effects 0.000 description 14
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 13
- 230000002147 killing effect Effects 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 241001430294 unidentified retrovirus Species 0.000 description 13
- 238000001994 activation Methods 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 12
- 239000012737 fresh medium Substances 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- 229960005322 streptomycin Drugs 0.000 description 11
- 108010062580 Concanavalin A Proteins 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
- 239000007995 HEPES buffer Substances 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 229930182555 Penicillin Natural products 0.000 description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 230000000139 costimulatory effect Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 229940049954 penicillin Drugs 0.000 description 9
- 108010086652 phytohemagglutinin-P Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 8
- 230000006801 homologous recombination Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000005909 tumor killing Effects 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 102100023132 Transcription factor Jun Human genes 0.000 description 6
- 102000013814 Wnt Human genes 0.000 description 6
- 108050003627 Wnt Proteins 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102000001764 CREB-Binding Protein Human genes 0.000 description 4
- 108010040163 CREB-Binding Protein Proteins 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- 108090000467 Interferon-beta Proteins 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 102000007327 Protamines Human genes 0.000 description 4
- 108010007568 Protamines Proteins 0.000 description 4
- 108090000315 Protein Kinase C Proteins 0.000 description 4
- 102000003923 Protein Kinase C Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 229950008679 protamine sulfate Drugs 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 108091033409 CRISPR Proteins 0.000 description 3
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 3
- 108091054729 IRF family Proteins 0.000 description 3
- 102100026720 Interferon beta Human genes 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 108700009124 Transcription Initiation Site Proteins 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000004940 costimulation Effects 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 102000055277 human IL2 Human genes 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000111 isothermal titration calorimetry Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009258 tissue cross reactivity Effects 0.000 description 3
- 230000005026 transcription initiation Effects 0.000 description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- -1 Cat#: LP0042) Substances 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102000016854 Interferon Regulatory Factors Human genes 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 2
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000011186 acute T cell leukemia Diseases 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 230000003081 coactivator Effects 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150110633 112 gene Proteins 0.000 description 1
- 101150030271 AXIN1 gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 102000051172 Axin Human genes 0.000 description 1
- 108700012045 Axin Proteins 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 101710181403 Frizzled Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000980303 Homo sapiens 10 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000793115 Homo sapiens Aryl hydrocarbon receptor nuclear translocator Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000043138 IRF family Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100388394 Mus musculus Dvl1 gene Proteins 0.000 description 1
- 101001043808 Mus musculus Interleukin-7 Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010057178 Osteoarthropathies Diseases 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700042076 T-Cell Receptor alpha Genes Proteins 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102000006290 Transcription Factor TFIID Human genes 0.000 description 1
- 108010083268 Transcription Factor TFIID Proteins 0.000 description 1
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- WKRWUYKLUMMAKG-WYGBAUISSA-L calcium;(4r,6s,8s,10z,12r,14r,16e,18r,19r,20s,21s)-19,21-dihydroxy-22-[(2s,5s)-5-[(2r,5s)-5-[(1r)-1-hydroxyethyl]-5-methyloxolan-2-yl]-5-methyloxolan-2-yl]-4,6,8,12,14,18,20-heptamethyl-11-oxido-9-oxodocosa-10,16-dienoate Chemical compound [Ca+2].O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/[O-])=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC([O-])=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 WKRWUYKLUMMAKG-WYGBAUISSA-L 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 238000002284 excitation--emission spectrum Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000006045 positive regulation of cell activation Effects 0.000 description 1
- 230000010644 positive regulation of cell differentiation Effects 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Definitions
- the present disclosure belongs to the field of cellular immunotherapy, and specifically relates to a self-regulating chimeric antigen receptor and its application in tumor immunity.
- the pathogen antigen stimulates T cells by binding to the T cell receptor (TCR), activates the signal transduction cascade, promotes the proliferation and differentiation of T cells, and finally eliminates the pathogen.
- TCR T cell receptor
- tyrosine kinase is phosphorylated, thereby activating downstream signal transduction pathways.
- T cells reorganize their cytoskeleton, changing their metabolism and gene expression.
- TCR TCR-dependent MAPK pathway
- AP-1 activator protein-1
- AP-1 dimer After AP-1 dimer is combined with AP-1 response element (AP-1-RE), it increases the transcription and expression of genes related to T cell activation.
- TCR can transmit signals through the LAT-SPL76 complex, thereby activating PKC ⁇ .
- the costimulatory factor CD28 can also signal through PI3K and PDK1 to activate PKC ⁇ .
- Activated PKCO causes IKK activation. It further causes phosphorylation of I ⁇ B ⁇ , leading to ubiquitination and degradation of I ⁇ B ⁇ , which causes nuclear translocation of NF- ⁇ B and combines with NF- ⁇ B response elements (NF- ⁇ B RE) to cause gene transcription (Suman P, Brian CS. A new look) at TCR signaling to NF- ⁇ B.
- Activated T cell nuclear factor is a type of transcription factor related to the calcium ion signaling pathway.
- the activated NFAT combines with the NFAT response element (NFAT-RE) to further regulate the development of lymphocytes. Activation and gene expression.
- T cell activation also includes Wnt pathway, Akt pathway and HIF1 ⁇ pathway.
- Wnt pathway In the classic Wnt pathway, the activation of Wnt requires the participation of Porc (O-palmitoleoyl transferase, O-palmitoleoyl transferase).
- Wnt binds to Frizzled on the cell membrane, it activates the scaffold protein in the cell matrix (Scaffold, which includes Dvl, GSK-3 ⁇ , axin, APC, ⁇ -catenin, etc.), and then activates the nuclear TCF/ LEF (T cell factor/lymphoid enhancer factor), regulates the transcription of downstream genes.
- Scaffold which includes Dvl, GSK-3 ⁇ , axin, APC, ⁇ -catenin, etc.
- TCF/ LEF T cell factor/lymphoid enhancer factor
- TCF/LEF is a type of transcription factor with two-way regulation function. Its response element is (TCF-RE). It can inhibit gene transcription when combined with Groucho, and it can promote the transcription of downstream target genes when combined with ⁇ -Catenin.
- FoxO transcription factor is the downstream target of PKB/Akt, and its response element is (FoxO RE). When Akt activity decreases, FoxOs is phosphorylated, FoxOs enters the nucleus, and binds to the DNA targeting sequence corresponding to the target gene to perform its transcription function.
- HIF is a family of heterodimer basic-helix-loop-helix transcription factors, and its hypoxia response element is HRE (hypoxia response element).
- HIF- ⁇ is hydroxylated by the factor of inhibiting HIF-1 (FIH) asparaginyl, thereby preventing HIF- ⁇ from binding to the co-activator protein p300/CBP.
- FIH HIF-1
- the activities of PHD and FIH are restricted by substrates, leading to rapid accumulation of HIF- ⁇ , nuclear translocation, and dimerization with HIF-1 ⁇ .
- HIF-1 binds to the DNA consensus sequence (a hypoxia response element (HRE)) in the promoter of the target gene, transactivation occurs.
- HRE hypoxia response element
- TATA box is a DNA sequence that RNA polymerase recognizes, binds and starts transcription, and it contains conserved sequences required for RNA polymerase specific binding and transcription initiation.
- the two most common core promoter elements associated with protein-coding genes are the TATA box and the initiator (Inr), which appear together or separately in most eukaryotic promoters.
- the TATA box is located 20-30bp upstream of the transcription initiation site (TSS), and serves as a binding site for the general transcription factor TFIID (Mathis DJ, Chambon P.
- TFS transcription initiation site
- TFIID general transcription factor
- the SV40 early region TATA box is required for accurate in vitro initiation of Nature.
- the conserved sequence of the initiator (Inr) is (YYA+1NT/AYY), which is often found in the core promoter of ubiquitously expressed or "housekeeping" genes, and initiates transcription at multiple discrete sites within a region of about 150 bp, independent Guide accurate transcription initiation (Smale ST, Baltimore D. The "initiator” as a transcription control element. Cell. 1989 Apr 7; 57(1): 103–113).
- TATA box and Inr Frith MC, Valen E, Krogh A, Hayashizaki Y, Carninci P, Sandelin AA code for transcription initiation in mmammalian genes. Genome Res.
- the TATA box mainly initiates the expression of tissue-specific genes such as IL-2 in T cells.
- the initiator (Inr) is used to initiate the expression of ubiquitously expressed or "housekeeping" genes. Therefore, the promoters of immunoglobulin genes and IL-2 genes only contain the TATA box, while the actin promoter only contains the initiator (Inr) element.
- RE Response element
- enhancers In response to different environmental stimuli, enhancers can have multiple different response elements and also bind different transcription factors, which together regulate gene expression. In a specific gene, repeated repetition of the same response element can enhance the regulatory effect.
- Enhancesome is a functional unit structure composed of enhancers, transcription factors and corresponding cofactors. It can change the structure of local chromosomes, recruit RNA polymerase II to the promoter, and regulate gene Express.
- IFN- ⁇ enhancer is a typical model for studying gene transcription regulation. It is located upstream of the transcription start site of IFN- ⁇ gene and can recruit some cofactors that can acetylate histone H1, such as p300/CREB binding protein (CBP) . The acetylated histones can relax the nucleosomes located in the TATA box, exposing the promoter, thereby promoting more transcription factors TFIIB and RNA polymerase II, causing the initiation of transcription.
- CBP p300/CREB binding protein
- IFN- ⁇ enhancer contains 4 positive regulatory domains (Postive regulatory domains, PRDs), interferon regulatory factor (interferon regulatory factor, IRF) combined with positive regulatory domain I (PRDI)) and positive regulatory domain III (PRDIII), NF- ⁇ B can be combined with positive regulatory region II (PRDII), and ATF-2/c-Jun can be combined with positive regulatory region IV (PRDIV).
- PRDs Postive regulatory domains, PRDs
- IRF interferon regulatory factor
- PRDI positive regulatory domain I
- PRDIII positive regulatory domain III
- NF- ⁇ B can be combined with positive regulatory region II (PRDII)
- ATF-2/c-Jun can be combined with positive regulatory region IV (PRDIV).
- These transcription factors can be combined with their coactivator (Coactivator), CBP, etc., to jointly regulate the transcription and expression of genes (Pan Y, Nussinov. The Role of Response Element Organization in Transcription Factor Seletivity: The IFN- ⁇ Enhance
- Chimeric antigen receptor modified T cell is a genetically modified T cell that uses gene transduction technology to contain single-chain antibodies that can specifically bind to tumor surface antigens (ScFv), receptors, ligands, protein scaffolds ((including Affibody, DARPin, Monobody (including Centyrin), Anticalin4, etc.)) or other new protein scaffolds and chimeric antigen receptor (CAR) introduction of T cell activation motifs Patient T cells (Alsultan, A., et al. Beyond Antibodies: Development of a Novel Protein Scaffold Based on Human Chaperonin 10.
- the antigen is activated to kill cancer cells (Schmitz M, et al. Chimeric antigen receptor-engineered T cells for immunotherapy of Cancer. J Biomed Biotechnol, 2010).
- the chimeric antigen receptor includes an extracellular binding domain, a transmembrane domain (TM), and an intracellular signal domain.
- TM transmembrane domain
- the extracellular region contains scFv, receptors, ligands, protein scaffolds (including Affibody, DARPin, Monobody (including Centyrin), Anticalin4, etc.) or other novel protein scaffolds capable of recognizing tumor-associated antigens.
- the transmembrane region adopts the transmembrane region of molecules such as CD8 and CD28, and the intracellular signal region adopts cells including immunoreceptor tyrosine activation motif (ITAM) CD3 ⁇ and costimulatory signal molecules CD28, CD137 (4-1BB), CD134, etc. Inner signal area.
- the intracellular signal region containing only CD3 ⁇ is designed as the first generation CAR-T lymphocytes, in which the parts of the chimeric antigen receptor are connected in the following form: scFv-TM-CD3 ⁇ .
- CAR T can stimulate anti-tumor cytotoxic effects, but the secretion of cytokines is relatively small, and it cannot stimulate long-lasting anti-tumor effects in the body (Zhang T.et al.Chimeric NKG2D-modified T cells inhibition systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways, Can Res 2007, 67(22): 11029–11036).
- CD28 or 4-1BB co-stimulation in the intracellular signal area causes the continuous proliferation of T lymphocytes, and can increase the level of IL-2 and IFN- ⁇ secreted by T lymphocytes, and at the same time increase CAR-T in vivo Survival cycle and anti-tumor effect (Dotti G.et al. CD28 costimulation improvement expansion and persistence of chimeric antigen receptor modified T cells in lymphoma patients.
- the engineered TCR-T can recognize intracellular proteins.
- the engineered TCR-T is composed of soluble TCR and the signal part of the CAR. Such a structure binds to the targeted antigen in an MHC I restricted manner, and performs the same signal transduction and tumor-killing functions as CAR-T (Walseng, E., et al. al. A TCR-based Chimeric Antigen Receptor. Sci Rep 7,10713 (2017)).
- Engineered TCR-T is a TCR ⁇ / ⁇ heterodimer modified by transduction affinity to improve the specific recognition of intracellular tumor-associated antigen (TAA) (Q Liu, et al. Cancer immunotherapy using T- cell receptor engineered T cell.Ann Blood 2020; 5; 5).
- TCR-T cell therapy includes the selection of tumor-specific TCR, TCR ⁇ / ⁇ heterodimer affinity modification, construction of TCR ⁇ / ⁇ expression vector, T cell transduction, cell reinfusion after TCR-T modification, immune process monitoring, etc. Technology and treatment. Compared with the same type of CAR-T cell therapy technology, TCR-T has a wider choice of antigens, so it can not only expand its applicable tumor range, but also is expected to reduce off-target effects.
- CAR-T cells in order to obtain higher anti-tumor activity, the expansion and maintenance of CAR-T cells in the body are two very important factors.
- CAR-T cells In traditional CAR-T cells, the expression of CAR is constitutive. Highly expressed ScFv, self-aggregation, will form basic signaling (Low-level “basal” or “tonic” signal).
- CAR-T cells expand well in vitro under the effect of tonic signaling, but they are difficult to maintain in vivo (Frigault MJ, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible). proliferation of T cells. Cancer Immunol. Res. 2015; 3: 356–367; Long AH, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 2015; 21: 581 -590).
- CRISPR/Cas9 technology to locate CAR on the TCR ⁇ gene, or replace the costimulatory factor CD28 with 4-1BB, although it can reduce the basic signal transduction (Eyquem J, et al. Targeting a CAR to the TRAC locus with CRISPR/ Cas9enhances tumor rejection.Nature.2017; 543:113–117), but because of its amplification on ⁇ -retroviral vectors, CAR-T has limited anti-tumor ability in vivo (Diogo G, et al. Tonic 4-1BB) Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector Dependent. Cell Rep. 2017; 21(1):17–26).
- the present disclosure aims to design a self-regulating CAR-T cell that has low expression of CAR before they are close to tumor antigens and has little cell-based activation.
- Gene expression self-regulating sequences can induce the expression of CAR or engineered TCR, and are suitable for different tumor targets.
- the tumor surface antigen binds to CAR-T surface scFv, receptor, ligand, protein scaffold or TCR, which will specifically activate CAR-T or TCR-T cells and promote more CAR-T cells or TCRs -
- the expression of CAR or TCR on the T surface further enhances the expansion ability of CAR-T cells or TCR-T cells and exerts the function of effector cells.
- This way of activating CAR-T locally through the tumor can effectively reduce the release of systemic cytokines that are not related to tumor surface antigens, reduce the toxic and side effects of CAR-T or TCR-T, and have a powerful tumor-killing effect.
- the present disclosure provides a tumor antigen-induced gene expression self-regulating nucleotide sequence, the sequence comprising: (1) a promoter sequence, and (2) an enhancer sequence.
- the present disclosure provides a nucleic acid construct comprising the aforementioned tumor antigen-induced gene expression self-regulating nucleotide sequence and a nucleotide sequence encoding a protein that specifically binds to the tumor antigen.
- the present disclosure provides the aforementioned tumor antigen-induced gene expression self-regulating nucleotide sequence and/or nucleic acid construct for preparing genetically modified immune cells directed against tumor-associated antigens.
- the present disclosure provides an isolated host cell comprising the aforementioned tumor antigen-induced gene expression self-regulating nucleotide sequence and/or nucleic acid construct.
- the present disclosure provides a pharmaceutical composition comprising the aforementioned tumor antigen-induced gene expression self-regulating nucleotide sequence, nucleic acid construct and/or host cell.
- the present disclosure provides a use of the aforementioned tumor antigen-induced gene expression self-regulating nucleotide sequence, nucleic acid construct and/or host cell and/or pharmaceutical composition in the preparation of medicines.
- the present disclosure provides a method for preparing CAR-T or TCR-T cells.
- the present disclosure provides a method for treating a tumor-associated antigen-related disease in a subject, which comprises administering to the subject a chimeric antigen receptor (CAR) nucleic acid construct, virus, or host cell, and / Or pharmaceutical composition.
- a chimeric antigen receptor (CAR) nucleic acid construct e.g., a chimeric antigen receptor (CAR) nucleic acid construct, virus, or host cell, and / Or pharmaceutical composition.
- CAR chimeric antigen receptor
- the gene expression control sequence formed by the combination of the enhancer of the present disclosure (such as NFAT-RE, NF- ⁇ B-RE, AP-1-RE, TCF-RE, HRE, etc.) and a promoter (such as IL-2 TATA box) can Induces the expression of CAR and is suitable for different tumor targets.
- the combination of the same enhancer and promoter can regulate the expression of different CARs in CAR-T or different engineered TCRs in TCR-T.
- the combination of different enhancers and IL-2 TATA box can not only regulate gene expression in Jurkat cells, but also play a role in PBMC or mouse spleen cells.
- CAR-T or TCR-T Once CAR-T or TCR-T comes into contact with the antigen, it will be quickly activated, thereby regulating and enhancing the expression of its own CAR or engineered TCR. Regulated CAR-T or TCR-T has a powerful tumor killing effect. Compared with CAR-T or TCR-T driven by the EF-1 ⁇ promoter, this adjustable CAR has a better killing effect in PBMC. . Such an adjustable structure can become another new way to treat tumors, including solid tumors.
- Figure 1 shows the main structure of the three types of plasmids designed by the present disclosure, in which Figure 1A is the first type of plasmid; Figure 1B is the second type of plasmid; Figure 1C is the third type of plasmid.
- Figure 2 shows the regulatory effects of PMA and ionomycin on Jurkat cells transduced with plasmid 112.
- Figure 3 shows the regulatory effect of enhancers on Jurkat cells transduced with plasmid 292 (expressing CD19 antigen).
- FIG. 4 shows the regulation effect of different stimuli on the PBMC transduced with plasmid 112.
- Figure 5 shows the timing of PMA and ionomycin stimulation on PBMC expression of genes.
- Figure 6 shows the regulatory effect of the combination of enhancer and IL-2 TATA box in PBMC.
- Figure 7 shows the modulatory effects of enhancers on different CARs.
- Figure 8 shows the antigen induction effects of different enhancers in PBMC or Jurkat.
- Figure 9 shows the flow cytometry (Figure 9A) and data analysis results (Figure 9B) of antigen-stimulated PBMC cells transduced with plasmid 260 and control cells.
- Figure 10 shows the regulatory effects of CAR-regulated structures and CAR non-regulated structures on CAR-T cells.
- Fig. 11 shows the antigen induction effect of the CAR regulatable structure in retrovirus-transduced Jurkat cells, wherein Fig. 11A is transduced with plasmid 417 and Fig. 11B is transduced with plasmid 440.
- Figure 12 shows the killing effect of inducible CAR-T, where Figure 12A shows the CAR after transduction of plasmids 245 and 260 in PBMC; Figure 12B shows the killing of PBMCs transduced with plasmids 245 and 260, respectively The killing rate of tumor cells.
- Figure 13 shows the expression of cytokines after PBMC transduced with plasmids 245 and 260 are incubated with target cells.
- Figure 14 shows the regulatory effect of the adjustable CAR in mouse spleen cells (SPL).
- the term "self-regulation" means that once CAR-T or TCR-T cells contact tumor cell surface antigens, CAR-T or TCR-T cells will be activated to produce more CARs or engineered TCRs. It further enhances the expansion ability of T cells and exerts the function of effector cells. This is a process that relies on its own components for regulation.
- scFv refers to a fusion protein that includes at least one light chain variable region antibody fragment and at least one heavy chain variable region antibody fragment, wherein the light chain and heavy chain variable regions pass through a short
- the flexible polypeptide linker is contiguous and can be expressed as a single-chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it is derived.
- scFv may have the VL and VH variable regions in any order (for example, relative to the N-terminus and C-terminus of the polypeptide), and the scFv may include VL-linker-VH or May include VH-Linker-VL.
- gene synthesis refers to the use of recombinant DNA technology or the use of synthetic DNA or amino acid sequence technology available and well-known in the art.
- the term "antigen" or "Ag” is defined as a molecule that elicits an immune response, which may involve the production of antibodies, or the activation of specific immunocompetent cells, or both.
- any macromolecule including virtually all proteins or polypeptides, can be used as an antigen.
- the antigen can be derived from recombinant or genomic DNA.
- the antigen need not be individually encoded by the full-length nucleotide sequence of the gene. It is obvious that the present disclosure includes, but is not limited to, the use of partial nucleotide sequences of more than one gene, and these nucleotide sequences are arranged in different combinations to elicit a desired immune response. In addition, the skilled person will understand that the antigen need not be encoded by a "gene”. It is obvious that antigens can be produced, synthesized, or derived from biological samples. Such biological samples may include, but are not limited to, tissue samples, tumor samples, cells, or biological body fluids.
- anti-tumor effect refers to a biological effect, which can be caused by a decrease in tumor volume, a decrease in the number of tumor cells, a decrease in the number of metastases, an increase in life expectancy, or various cancerous disorders. The improvement of physical symptoms is clearly indicated.
- the "anti-tumor effect” can also be clearly expressed by the ability of the peptides, polynucleotides, cells and antibodies of the present disclosure to prevent tumors from occurring in the first place.
- cancer is defined as a disease characterized by the rapid and uncontrolled growth of aberrant cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body. Examples of various cancers include, but are not limited to, brain cancer (such as astrocytoma, meningioma, oligodendroglioma, glioma, etc.), pancreatic cancer, ovarian cancer, kidney cancer, bladder cancer, pancreatic cancer, Stomach cancer, bowel cancer, head and neck cancer, thyroid cancer, prostate cancer, Kaposi's sarcoma, etc.
- brain cancer such as astrocytoma, meningioma, oligodendroglioma, glioma, etc.
- pancreatic cancer ovarian cancer
- kidney cancer bladder cancer
- pancreatic cancer Stomach cancer
- bowel cancer bowel cancer
- head and neck cancer thyroid cancer
- prostate cancer Kaposi's sarcoma
- inflammatory disease examples include, but are not limited to, asthma, encephalitis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), allergy, septic shock, pulmonary fibrosis, undifferentiated Spondyloarthropathy, undifferentiated osteoarthropathy, arthritis, inflammatory osteolysis, and chronic inflammation caused by chronic viral and bacterial infections.
- COPD chronic obstructive pulmonary disease
- costimulatory molecule refers to an associated binding partner on T cells that specifically binds to a costimulatory ligand, thereby mediating the costimulatory response of T cells, such as but not limited to proliferation, costimulatory molecules Including but not limited to MHC I molecules, BTLA and Toll ligand receptors.
- costimulatory signal refers to a signal that combines with a primary signal, such as TCR/CD3 linkage, leading to T cell proliferation and/or up- or down-regulation of key molecules.
- expression is defined as the transcription and/or translation of a specific nucleotide sequence driven by its promoter.
- nucleic acid construct refers to a vector that includes a recombinant polynucleotide that includes an expression control sequence operably linked to the nucleotide sequence to be expressed.
- the nucleic acid construct includes sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system.
- Nucleic acid constructs include all those known in the art, such as cosmids incorporating recombinant polynucleotides, plasmids (e.g., naked or contained in liposomes), and viruses (e.g., lentivirus, retrovirus, adenovirus) And adeno-associated virus).
- homologous refers to sequence similarity or sequence identity between two polypeptides or between two nucleic acid molecules.
- a position in two comparison sequences is occupied by the same base or amino acid monomer subunit, for example, if the position in each of two DNA molecules is occupied by adenine, then the molecules are the same at that position.
- Source. The percent homology between two sequences is a function of the number of matches or homologous positions shared by the two sequences divided by the number of positions compared ⁇ 100. For example, if 6 out of 10 positions in two sequences are matched or homologous, then the two sequences are 60% homologous. Take an example to illustrate that the DNA sequences ATTGCC and TATGGC share 50% homology. Generally, when two sequences need to be aligned to give maximum homology, a comparison is made.
- a "polynucleotide sequence encoding an amino acid sequence” includes all nucleotide sequences that are degenerate versions of each other and encode the same amino acid sequence.
- the nucleotide sequence encoding a protein or RNA may also include introns to the extent that the nucleotide sequence encoding the protein may include intron(s) in some versions.
- parenteral administration of immunogenic compositions includes, for example, subcutaneous (s.c.), intravenous (i.v.), intramuscular (i.m.) or intrasternal injection, or injection techniques.
- the terms "patient”, “subject”, “individual”, etc. are used interchangeably herein and refer to any animal or cell thereof that is subject to the methods described herein, whether in vitro or in situ.
- the patient, subject, or individual is a human.
- nucleic acid is a polymer of nucleotides. Therefore, nucleic acids and polynucleotides as used herein are interchangeable. Those skilled in the art have the general knowledge that nucleic acids are polynucleotides that can be hydrolyzed into monomeric "nucleotides”. Monomer nucleotides can be hydrolyzed into nucleosides.
- Polynucleotides as used herein include, but are not limited to, all nucleic acid sequences obtained by any means available in the art, including but not limited to recombinant means, that is, from a recombinant library or cell genome, using common cloning techniques and PCR And so on clone nucleic acid sequence, and synthetic means.
- peptide As used herein, the terms “peptide”, “polypeptide” and “protein” are used interchangeably and refer to a compound composed of amino acid residues covalently linked by peptide bonds.
- the protein or peptide must contain at least two amino acids, and the maximum number of amino acids in its sequence is not limited.
- a polypeptide includes any peptide or protein that includes two or more amino acids connected to each other by peptide bonds.
- short chains which are also commonly referred to in the art as peptides, oligopeptides, and oligomers, for example; and longer chains, which are commonly referred to as proteins in the art, have many types.
- Polypeptide includes, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, polypeptide variants, modified polypeptides, derivatives, analogs, fusion proteins, and the like. Polypeptides include natural peptides, recombinant peptides, synthetic peptides or a combination thereof.
- promoter is defined as the initiation of the specific transcription of a polynucleotide sequence, recognized by the synthesis machinery of the cell, or a DNA sequence that guides the synthesis machinery.
- promoter/regulatory sequence refers to a nucleic acid sequence required for the expression of a gene product operably linked to the promoter/regulatory sequence.
- the sequence may be a core promoter sequence, and in other examples, the sequence may also include enhancer sequences and other regulatory elements required for expression of the gene product.
- the promoter/regulatory sequence can be, for example, a sequence that expresses a gene product in a tissue-specific manner.
- the term "constitutive" promoter is a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, allows most cells to produce a gene product under all physiological conditions.
- inducible promoter is a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, such that only the corresponding promoter inducer is present in the cell to produce Gene product.
- immunospecifically binds or “immune-specifically binds” with regard to an antibody or an antigen-binding fragment thereof are used interchangeably herein, and refers to an antibody or an antigen-binding fragment passing through the antibody binding site of the antibody and the antigen.
- the antigen may be an isolated antigen or present in tumor cells.
- immunospecifically bind (or specific binding) of the antibodies to the antigen is approximately 1 ⁇ 10 7 M -1 or 1x10 8 M -1 or greater affinity constant Ka (1x10 -7 M or 1 ⁇ 10 - A dissociation constant (Kd) of 8 M or lower) binds the antigen.
- the affinity constant can be determined by standard kinetic methods of antibody reaction, for example, immunoassay, surface plasmon resonance (SPR) (Rich and Myszka (2000) Curr. Opin. Biotechnol 11: 54; Englebienne (1998) Analyst. 123: 1599), isothermal titration calorimetry (ITC) or other kinetic interaction assays known in the art (see, for example, Paul, ed., Fundamental Immunology, 2nd ed., Raven Press, New York, pages 332-336 (1989); see also U.S. Patent No. 7,229,619 describing exemplary SPR and ITC methods for calculating the binding affinity of antibodies).
- SPR surface plasmon resonance
- ITC isothermal titration calorimetry
- the viral transduction background value refers to the transduction of the target gene into T lymphocytes through a viral vector, so that the target gene is expressed in the T lymphocytes.
- the efficiency of viral transduction was tested by flow cytometry.
- the expression percentage of fluorescent protein (such as EGFP) or MFI is the viral transduction background value.
- window or regulatory window refers to the expression percentage of fluorescent protein (e.g. EGFP) or the expression of MFI and unstimulated fluorescent protein (e.g. EGFP) after a cell transduced with a target gene is stimulated by an antigen or other stimulating factor
- the percentage or the ratio of MFI is the window or adjustment window.
- the term "therapeutic" means treatment and/or prevention.
- the therapeutic effect is obtained through the suppression, alleviation or eradication of the disease state.
- treating refers to reducing the frequency or severity of at least one sign or symptom of a disease or disorder experienced by a subject.
- carrier is a composition of matter, which includes an isolated nucleic acid, and which can be used to deliver the isolated nucleic acid to the inside of a cell.
- vectors are known in the art, including but not limited to linear polynucleotides, polynucleotides related to ionic or amphiphilic compounds, plasmids, and viruses. Therefore, the term “vector” includes autonomously replicating plasmids or viruses. The term should also be interpreted to include non-plasmid and non-viral compounds that facilitate the transfer of nucleic acids into cells, such as, for example, polylysine compounds, liposomes, and the like. Examples of viral vectors include, but are not limited to, lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, and the like.
- an enhancer response element is provided herein, the enhancer response element is selected from NFAT-RE, NF- ⁇ B-RE, AP-1-RE, TCF-RE, HRE, and is selected from the following
- the nucleotide sequence of has at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90 %, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identity: SEQ ID NO: 120-128.
- the present disclosure provides a tumor antigen-induced gene expression self-regulating nucleotide sequence, the sequence comprising:
- the promoter is selected from the initiator, the TATA box and/or other core promoter elements, and the other core promoter elements are selected from the following elements : BREu (upstream TFIIB Recognition Element), MTE (Motif Ten Element), DPE (Downstream Promoter Element), DCE (Downstream Core Element), XCPE1 (X Core Promoter Element 1), etc.
- the TATA box is an IL-2 TATA box.
- the enhancer is selected from the following response elements: activated T cell nuclear factor response element (NFAT-RE), nuclear factor ⁇ B response element (NF- ⁇ B) -RE), T-cytokine/lymph enhancement factor response element (TCF-RE), activator protein-1 response element (AP-1-RE), hypoxia-inducible factor response element (HRE), FoxO transcription factor response element (FoxO -RE).
- NFAT-RE activated T cell nuclear factor response element
- NF- ⁇ B response element nuclear factor ⁇ B response element
- TCF-RE T-cytokine/lymph enhancement factor response element
- AP-1-RE activator protein-1 response element
- HRE hypoxia-inducible factor response element
- FoxO transcription factor response element FoxO transcription factor response element
- the tumor antigen is a tumor-associated antigen on the surface of tumor cells.
- the enhancer is a single-copy enhancer, a multi-copy enhancer, or a combination of different enhancers.
- the sequence and the following sequence have at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83 %, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identity: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23,
- the nucleotide sequence of the enhancer single-copy response element is selected from the following sequences: SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID: 128; or at least 60%, 65%, 70%, 75%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, A sequence of 98%, 99%, 99.5%, or 99.9% identity.
- the multiple copies are repeated 2-20 copies; particularly preferably, the multiple copies are repeated 2-9 times or repeated 2-7 Copies; more preferably, the multiple copies are repeated 5-6 copies.
- the nucleotide sequence of the enhancer multi-copy response element is selected from the following sequences: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO :11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14; or at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83% of the above sequence , 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% % Or 99.9% identity sequence.
- the single-copy reverse nucleotide sequence is SEQ ID NO: 126 or SEQ ID NO: 127; or is at least 60% with the above sequence. %, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, Sequences that are 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identical.
- the multi-copy reverse nucleotide sequence is SEQ ID NO: 15 or SEQ ID NO: 119; %, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, Sequences that are 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identical.
- the nucleotide sequence of the combined response element of the different enhancer is selected from the following sequences: SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24; or at least 60%, 65%, 70% of the above sequence , 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95 %, 96%, 97%, 98%, 99%, 99.5% or 99.9% identity sequence.
- the nucleotide sequence of the promoter is SEQ ID NO: 16; or at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95% , 96%, 97%, 98%, 99%, 99.5%, or 99.9% identity sequence.
- the present disclosure provides a nucleic acid construct comprising the aforementioned tumor antigen-induced gene expression self-regulating nucleotide sequence and a nucleotide sequence encoding a protein that specifically binds to tumor antigens; preferably, the The tumor antigen is a tumor-associated antigen on the surface of tumor cells.
- the protein capable of specifically binding to tumor antigens is selected from the group consisting of single-chain antibodies (ScFv), receptors, ligands, protein scaffolds and/or other chimeric antigen receptors (CAR );
- the protein scaffold is selected from Affibody, DARPin, Monobody, Anticalin4; preferably, the monomer is Centyrin; more preferably, the protein that can specifically bind to tumor antigens is a Combined antigen receptor (CAR).
- the chimeric antigen receptor comprises a tumor-associated antigen binding domain, a transmembrane domain and a signal transduction domain; preferably, the chimeric antigen receptor (
- the amino acid sequence of CAR) is SEQ ID NO: 26 or SEQ ID NO: 28; or at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84% of the above sequence , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9 % Identity sequence.
- the nucleotide sequence encoding the chimeric antigen receptor (CAR) is SEQ ID NO: 25 or SEQ ID NO: 27; or at least 60%, 65% of the above sequence , 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94 %, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identity sequence.
- the nucleotide sequence encoding the chimeric antigen receptor (CAR) is selected from SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, and SEQ ID NO: 109; or at least 60%, 65%, 70%, 75%, 80% of the above sequence , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98%, 99%, 99
- nucleic acid construct according to any one of the foregoing aspects, which is a cosmid, a plasmid or a viral vector or a non-viral vector.
- the viral vector is selected from a lentiviral vector, a retroviral vector, an adenovirus vector, and an adeno-associated virus vector.
- the non-viral vector is selected from Sleeping Beauty plasmid transposition system, PiggyBac system or minicircle DNA.
- the nucleic acid sequence of the nucleic acid construct is selected from: SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114 , SEQ ID NO: 115, SEQ ID NO: 116 and SEQ ID NO: 117; or at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84 %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or Sequence with 99.9% identity.
- the present disclosure provides the aforementioned tumor antigen-induced gene expression self-regulating nucleotide sequences and/or nucleic acid constructs for preparing genetically modified immune cells directed against tumor-associated antigens.
- the present disclosure provides an isolated host cell comprising the aforementioned tumor antigen-induced gene expression self-regulating nucleotide sequence and/or nucleic acid construct; preferably, the host cell is a mammalian cell; Preferably, the host cell is PBMC, T cell, NK cell, NKT cell, macrophage or cell line; preferably, the host cell is a primary cultured T cell; preferably, the host cell is selected from HEK293, HEK293T or Jurkat.
- the host cell also expresses other sequences, the other sequences including cytokine, another CAR, chemokine receptor, siRNA that reduces PD-1 expression, or protein that blocks PD-L1, TCR, or safety switch.
- the cytokine is selected from IL-12, IL-15, IL-21, or type I interferon.
- the chemokine receptor is selected from CCR2, CCR5, and CXCR3.
- the safety switch is selected from iCaspase-9, Truncated EGF.
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising the aforementioned tumor antigen-induced gene expression self-regulating nucleotide sequence, nucleic acid construct and/or host cell, and a pharmaceutically acceptable carrier.
- the present disclosure provides a use of the aforementioned tumor antigen-induced gene expression self-regulating nucleotide sequence, nucleic acid construct, host cell and/or pharmaceutical composition in the preparation of medicines.
- the drug is used to diagnose, treat or prevent one or more of cancer, inflammatory disease, and autoimmune disease.
- the drug is used for the diagnosis, treatment or prevention of tumors
- the tumor is selected from blood cancer and solid tumors; more preferably, the drug is used for diagnosis, treatment or prevention of blood
- the cancer is selected from one or more of leukemia, lymphoma, and myeloma; more preferably, the solid tumor used by the drug for diagnosis, treatment or prevention is selected from lung cancer, liver cancer, esophageal cancer, pancreatic cancer, ovarian cancer, and kidney cancer , Bladder cancer, pancreatic cancer, gastric cancer, bowel cancer, prostate cancer, one or more of them.
- the present disclosure provides a method for preparing CAR-T or TCR-T cells, the method comprising the following steps:
- nucleic acid construct expressing a self-inducible CAR or engineered TCR, the nucleic acid construct comprising the tumor antigen-induced gene expression self-regulating nucleotide sequence of claim 1 or 2 and a nucleotide sequence encoding a tumor antigen
- the nucleotide sequence of the protein that specifically binds preferably, the nucleic acid construct is selected from a cosmid, a plasmid, a viral vector or a non-viral vector; preferably, the viral vector is selected from a lentiviral vector, a retroviral vector, Adenovirus vector, adeno-associated virus vector; preferably, the non-viral vector is selected from Sleeping Beauty plasmid transposition system, PiggyBac system or minicircle DNA; preferably, packaging cell line is used to package the virus;
- step (3) Transducing the nucleic acid construct described in step (1) into the T lymphocytes described in step (2) to obtain T lymphocytes containing the construct; preferably, a viral vector or a non-viral vector Transduction into T lymphocytes;
- the present disclosure provides a method for treating a tumor-associated antigen-related disease in a subject, which comprises administering the aforementioned nucleic acid construct, host cell and/or pharmaceutical composition to the subject; preferably Preferably, the subject is a mammal; more preferably, the subject is a human.
- the backbone vector of synthetic plasmid 112 is pCDH-CMV-MCS-EF1-Puro (System Bioscience, Cat#: CD510B-1), and the backbone vector of synthetic plasmid 169 is pMSCV PIG (Puro IRES GFP empty vector) (Addgene 21654).
- PCR primers were synthesized by Nanjing GenScript Biotechnology Co., Ltd.
- Plasmid 112 was constructed by Suzhou Jinweizhi Biotechnology Co., Ltd.
- High pure dNTPs High pure dNTPs, Cat#: AD101
- Easy Taq DNA polymerase Easy Taq DNA polymerase, Cat#: AP111
- Trans 2K plusII DNA Marker Cat#: BM121
- Trans5 ⁇ chemically competent cells Trans5 ⁇ Chemically competitive cell, Cat#:CD201
- Homologous recombination enzyme Assembly Mix (Cat#: RN1020) was purchased from Suzhou Hongxun Biotechnology Co., Ltd.
- Tryptone TRYPTONE, Cat#: LP0042
- yeast extract YEAST EXTRACT, Cat#: LP0021
- Agar Agar was purchased from BIOSHARP.
- Jurkat Clone E6-1 cells (human acute T cell leukemia cell line) originated from ATCC TIB-152, HEK293T cells (human embryonic kidney cell line) In ATCC CRL-3216, NIH3T3 cells (mouse fibroblast cell line) are derived from ATCC CRL-1658.
- Penicillin-Streptomycin 100 ⁇ solution (Penicillin-Streptomycin 100 ⁇ solution, Cat#: SV30010) was purchased from Hyclone.
- Phorbol 12-myristate 13-acetate (Phorbol 12-myristate 13-acetate (PMA), Cat#: P8139-1MG), Dimethyl sulfoxid (DMSO), Cat#: D2650), Phytohaemagglutinin P (PHA-P for short, Cat#: L8754), Concanavalin A (Concanavalin A for short, Con-A, Cat#: L7647-25MG) were all purchased from Sigma -Aldrich.
- 2.7 Ionomycin Calcium Salt (Cat#: FMS-FZ 208) was purchased from Nanjing Formax Biotechnology Co., Ltd.
- CytoTell TM Blue (Cat#: 22251) was purchased from AAT Bioquest.
- Antibiotic puromycin (puromycin, Cat#: ant-pr-5) and blasticidin (Blasticidin, Cat#: ant-bl-05) were purchased from InvivoGen.
- Ficoll-Paque Plus (endotoxin tested ⁇ 0.12EU/ml, Cat#:17-1440-02) was purchased from GE Healthcare.
- Red blood cell lysate (Cat#: C3702) was purchased from Beyotime.
- the medium in the 6-well plate contains 10% FBS, 100U/ml penicillin, 100 ⁇ g/ml streptomycin+25uM chloroquine
- the medium contains 10% FBS, 100U/ml penicillin, 100 ⁇ g/ml streptomycin+25uM chloroquine
- the transfection solution was mixed gently and transferred to a 37°C, 5% CO 2 incubator. 16 hours after transfection, the medium was changed to a fresh medium containing 1 mM sodium butyrate. After 48 hours, collect the cell culture supernatant to obtain a virus liquid containing lentiviral particles.
- the virus solution obtained in step (1) was centrifuged at 132 g for 5 min to remove cell debris, and the virus supernatant was filtered through a 0.45 ⁇ m syringe filter, and then concentrated using an ultrafiltration tube. After the ultrafiltration tube was soaked in 20% ethanol overnight, 4ml of normal saline was added, centrifuged at 3000g for 15min, and the ultrafiltration tube was washed twice with sterile normal saline. Then add 4ml of normal saline and let it stand for 1 min, then remove the normal saline. Then the virus solution was added to the ultrafiltration tube, centrifuged at 3000g for 30 minutes, to obtain the concentrated virus solution, which was stored at -80°C.
- the Jurkat cells were collected, centrifuged at 100g for 10 min, and the supernatant was removed, replaced with fresh medium, and the cells were inoculated back to a 24-well plate at 37°C, 5% CO 2 incubator for 48 hours.
- virus packaging mix 200 ⁇ l 150mM NaCl, 2.5 ⁇ g or 2 ⁇ g target plasmid, 0.5 ⁇ g packaging plasmid VSVG or 1 ⁇ g packaging plasmid pCL-Eco (Addgen 12371) and 21 ⁇ l PEI into a transfection solution, vortex and shake for 8 seconds, and let stand at room temperature 10min.
- the medium in the 6-well plate contains 10% FBS, 100U/ml penicillin, 100 ⁇ g/ml streptomycin+25uM chloroquine
- the medium contains 10% FBS, 100U/ml penicillin, 100 ⁇ g/ml streptomycin+25uM chloroquine
- the transfection solution was mixed gently and transferred to a 37°C, 5% CO 2 incubator. 16 hours after transfection, the medium was changed to a fresh medium containing 1 mM sodium butyrate. After 48 hours, collect the cell culture supernatant to obtain a virus liquid containing retroviral particles.
- the method is the same as the lentivirus concentration step (2).
- transduction Jurkat and virus titer is the same as that of lentivirus.
- MFI Median Fluorescence Intensity
- the steps for preparing hPBMC are as follows:
- Day 0 Take out a tube of frozen hPBMC from liquid nitrogen and quickly melt it in a 37°C water bath. Gently add hPBMC dropwise to 3ml of pre-warmed complete medium (90%RPMI 1640+10%FBS+100U/ml penicillin+100 ⁇ g/ml streptomycin+10mM HEPES), and centrifuge at 500g for 5min. After removing the supernatant, resuspend the cells in 3ml medium and take 10 ⁇ l of the cell suspension for counting. According to the counting results, 1 ⁇ 10 5 cells were seeded in a 96-well plate (round bottom), and a certain volume of culture medium was added to make the total volume 200 ⁇ l.
- pre-warmed complete medium 90%RPMI 1640+10%FBS+100U/ml penicillin+100 ⁇ g/ml streptomycin+10mM HEPES
- the Dynabeads need to be washed once in accordance with the steps in the product instructions before use.
- 100IU/ml human interleukin-2 was added, and after gently mixing, the 96-well plate was placed in a 37°C, 5% CO 2 incubator for 24 hours.
- Day 1 Gently pipette 110 ⁇ l of supernatant (do not touch the cells), and discard. Take another 500 ⁇ l EP tube, add virus, 100ng/ml Protamine Sulfate, 20mM HEPES, and mix gently (the amount of protamine sulfate and HEPES added is calculated based on the total medium in the 96-well plate) .
- the prepared virus suspension was added dropwise to hPBMC, and centrifuged at 800g at 32°C for 2h. After the end, the plate was placed in a 37°C, 5% CO 2 incubator to continue culturing.
- Day 2 Take a 500 ⁇ l EP tube, add virus, 100ng/ml protamine sulfate, and mix gently (the amount of protamine sulfate added is calculated based on the volume of the virus).
- Day 3 Change the medium: remove 100 ⁇ l of supernatant (do not touch the cells), and then add 100 ⁇ l of complete medium.
- Day 4 Transfer the cells from the 96-well plate to the 24-well plate for culture, and add 250 ⁇ l of complete medium.
- Day 5 Change the medium: remove 220 ⁇ l of supernatant, and then add 650 ⁇ l of complete medium.
- Day 6 Transfer the cells in 24 wells once to two, and add 500 ⁇ l of complete medium to each well.
- Day 7 Inoculate the cells in two 24-wells into a T25 culture flask and maintain the cell density at 5 ⁇ 10 5 -1 ⁇ 10 6 cells/ml. From now on, cells can be maintained in T25, counted every other day, and replaced with fresh medium. The cell seeding density is 5 ⁇ 10 5 -1 ⁇ 10 6 cells/ml.
- Day 0 Place the mouse spleen in a 10cm dish, add 5ml DMEM medium, gently grind the mouse spleen with 2 glass slides (rough side), and pass the cell suspension through a 70-mesh screen Filter and collect in a 50ml centrifuge tube. Then rinse the 10cm dish with 5ml DMEM medium, and filter and collect it in the same way. Let stand at room temperature for 1 min. Transfer the supernatant to a new 15ml centrifuge tube and centrifuge at 500g for 5min. After removing the supernatant, add 1.5ml of red blood cell lysate, leave it at room temperature for 6 minutes, and add 10ml of DPBS to stop the reaction.
- 5ml DMEM medium gently grind the mouse spleen with 2 glass slides (rough side), and pass the cell suspension through a 70-mesh screen Filter and collect in a 50ml centrifuge tube. Then rinse the 10cm dish with 5ml DMEM medium, and filter and collect
- Day 1 Gently pipette 600 ⁇ l of cell supernatant into a 1.5ml EP tube, centrifuge at 500g for 5min. After removing the supernatant, add 100 ⁇ l of complete medium to resuspend the cells, and then add virus, 2 ⁇ g/ml Lipo2000 (ThermoFisher), 1.6 ⁇ g/ml Polybrene. Lipo2000 and Polybrene are calculated based on a total volume of 500 ⁇ l. After mixing, add dropwise to a 24-well plate, centrifuge at 930g at 37°C for 1.5h. After centrifugation, add 500 ⁇ l of complete medium, 37°C, 5% CO 2 incubator to continue culturing.
- D1 Gently pipette 600 ⁇ l of cell supernatant into a 1.5ml EP tube, centrifuge at 500g for 5min. After removing the supernatant, add 100 ⁇ l of complete medium to resuspend the cells, and then add virus, 2 ⁇ g/ml Lipo2000 (
- Day 2 (D2): Remove 500 ⁇ l of cell supernatant, taking care not to touch the cells. After gently mixing the cells, take 10 ⁇ l and count. According to the cell count results, the cells in the 24-well plate were transferred to T25 culture flasks for culture. The inoculation cell density was 2 ⁇ 10 5 cells/ml, and the total volume was 6 ml. From this time on, the cells can be maintained in T25 and the cell density is maintained at 4 ⁇ 10 5 -1 ⁇ 10 6 cells/ml. Because the cells grow rapidly, it is necessary to count and replace with fresh medium every day.
- CD20 CAR was synthesized by Suzhou Jinweizhi Biotechnology Co., Ltd., and its nucleotide sequence is: SEQ ID NO: 25, and its amino acid sequence is: SEQ ID NO: 26.
- CD19 CAR was synthesized by Suzhou Jinweizhi Biotechnology Co., Ltd., and its nucleotide sequence is: SEQ ID NO: 27, and its amino acid sequence is: SEQ ID NO: 28.
- this example uses response elements combined with transcription factors related to T cell receptor (TCR) gene transcription regulation as enhancers, and designed a single connection or multiple Copy the linked response elements to regulate gene expression.
- the response elements include AP-1-RE (MAPK pathway), NF- ⁇ B-RE (NF- ⁇ B pathway), NAFT-RE (calcium pathway), FoxO-RE (PKB/Akt pathway), TCF-RE (Wnt Pathway), HRE (HIF1a pathway).
- the nucleotide sequence of a single copy of NF- ⁇ B-RE is SEQ ID NO: 120 or 121; the nucleotide sequence of a single copy of NAFT-RE is SEQ ID NO: 122; the nucleotide sequence of a single copy of TCF-RE It is SEQ ID NO: 123; the nucleotide sequence of HRE single copy is SEQ ID NO: 124; the nucleotide sequence of AP-1-RE single copy is SEQ ID NO: 125; NF- ⁇ B reverse single copy nucleus
- the nucleotide sequence of the nucleotide sequence is SEQ ID NO: 126; the nucleotide sequence of the reverse single copy of NAFT-RE is SEQ ID NO: 127; the nucleotide sequence of the single copy of FoxO-RE is SEQ ID NO: 128.
- the first type of plasmid contains enhancer, IL-2 TATA promoter (SEQ ID NO: 16) and EGFP (enhancer-IL-2 TATA promoter-EGFP), and its main structure As shown in Figure 1A, plasmids 112, 241, 242, 243-1, 243-5, 244, 262, 293, 417, 445, 446, 459, and 460 are involved.
- the second type of plasmid contains enhancer, IL-2 TATA promoter, CAR, mouse IL-7 and EGFP (enhancer-IL-2 promoter-CAR-F2A-IL-7-F2A-EGFP), the main structure is as follows As shown in Figure 1B, plasmids 228, 259, 260, 261, 263, 280, 281, 292, 294, 407, 410, 437, 438-13, 438-18, 439, 440, 448 are involved.
- the third type of plasmid contains EF1 ⁇ enhancer, EF1 ⁇ promoter, CAR, murine IL-7 and EGFP (EF1 ⁇ enhancer-EF1 ⁇ promoter-CAR-F2A-IL-7-F2A-EGFP), and its main structure is shown in Figure 1C As shown, plasmid 245 is involved.
- Plasmids 026, 056, 099, 112, 245, and 169 are all synthesized by Suzhou Jinweizhi Biotechnology Co., Ltd., and their nucleotide sequences are: SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 118.
- the enhancers NFAT-RE (SEQ ID NO: 1), NF- ⁇ B-RE (SEQ ID NO: 2 or 3), TCF-RE (SEQ ID NO: 4 or 5), FoxO-RE (SEQ ID NO: 2 or 3), TCF-RE (SEQ ID NO: 4 or 5) were synthesized by conventional molecular biology PCR.
- RE SEQ ID NO: 6
- HRE SEQ ID NO: 7
- AP-1-RE SEQ ID NO: 8
- IFN- ⁇ enhancesome-RE SEQ ID NO: 21, 22, 23 or 24
- the enhancer was homologously recombined into the plasmid 112ClaI and EcoRV restriction sites.
- the molecular cloning techniques involved in this disclosure are all conventional techniques of molecular biology.
- PMA and ionomycin can usually be used to stimulate the cells to study the activation mechanism of T cells.
- PMA is an activator of protein kinase C (PKC).
- PKC protein kinase C
- PKC can activate the phosphorylation of many downstream protein kinases to form a cascade reaction and induce the expression of many proteins through NFAT.
- DAG diacylglycerol
- Ca 2+ Ca 2+
- Ionomycin is a transport agent of Ca 2+, the intracellular Ca 2+ can be transported to the cytoplasm, thus contributing to T-cell activation. Therefore, PMA and ionomycin can synergistically activate T cells, and can detect the expression of genes related to TCR induction.
- Jurkat cells are an acute T cell leukemia cell line, which retains the signal transduction function of T cells and has a wide range of applications in cell biology research on T cell functions.
- the NFAT enhancer and IL-2 TATA box were combined, and EGFP was used as the reporter gene. They were constructed into a lentiviral vector, and then HEK293T cells were used to package the virus, and the plasmid 112 was transduced to Test its regulatory effect in Jurkat cells.
- This example first selected some enhancers related to T cell activation, such as AP-1-RE (MAPK pathway), NF- ⁇ B-RE (NF- ⁇ B pathway), NFAT-RE (Ca + pathway), TCF- RE (Wnt pathway), FoxO-RE (Akt pathway), HRE (HIF1 ⁇ pathway), combine them with IL-2 TATA box and EGFP through homologous recombination, and then transduce them into Jurkat cells through lentivirus , And stimulated with PMA/Iono. After 24h, flow cytometry was used to detect the expression of EGFP in each combination. The expression of EGFP can reflect the ability of different enhancers to induce gene expression.
- enhancers related to T cell activation such as AP-1-RE (MAPK pathway), NF- ⁇ B-RE (NF- ⁇ B pathway), NFAT-RE (Ca + pathway), TCF- RE (Wnt pathway), FoxO-RE (Akt pathway), HRE (HIF1 ⁇ pathway)
- the above-mentioned different enhancers and the IL-2 TATA box were homologously recombined into the vector expressing CD20 CAR, and the structure is RE-IL-2 TATA box-CAR-F2A-IL -7-F2A-EGFP (plasmid 228, 259, 263, 294).
- this example also combined different REs to obtain the following plasmid: 260 (including enhancer NFAT-RE ⁇ NF- ⁇ B-RE, and its nucleotide sequence is as SEQ ID NO: 17), 261 (including the enhancer NF- ⁇ B-RE ⁇ NFAT-RE, and its nucleotide sequence is shown in SEQ ID NO: 18), 280 (including the enhancer NFAT-RE ⁇ HRE-RE , Its nucleotide sequence is shown in SEQ ID NO: 19), 281 (including the enhancer HRE-RE ⁇ NFAT-RE, and its nucleotide sequence is shown in SEQ ID NO: 20), 445 (including the enhancer IFN - ⁇ enhancesome(1)-RE, whose nucleotide sequence is shown in SEQ ID NO: 21) and plasmid 446 (including enhancer IFN- ⁇ enhancesome(2)-RE, whose nucleotide sequence is shown in SEQ ID NO: 22)
- the response element is a highly conserved DNA sequence with independent or multiple copies of enhancers.
- This example also uses enhancers NF- ⁇ B-RE, HRE and AP-1-RE as examples to discuss different copy numbers.
- the regulatory role of the enhancer is a highly conserved DNA sequence with independent or multiple copies of enhancers.
- NF- ⁇ B-RE, HRE and AP-1-RE used in the previous article are all 3 repeats, but here we use the PCR method to synthesize 3, 4 and 11 NF- ⁇ B-REs, 6 With 9 HRE repeats and 6 AP-1-RE repeats, and through homologous recombination, the following plasmids were obtained: 410 (6 NF- ⁇ B-RE, SEQ ID NO: 9), 407 (7 NF- ⁇ B-RE, SEQ ID NO: 10), 437 (11 NF- ⁇ B-RE, SEQ ID NO: 11), 438-18 (6 HRE, SEQ ID NO: 12), 438-13 ( Nine HREs, SEQ ID NO: 13) and 439 (6 AP-1-REs, SEQ ID NO: 14).
- HEK293T was used to package the viruses, and they were transduced into Jurkat cells via lentivirus, and then stimulated with PMA/Iono for 24h, and finally, the expression of EGFP was detected by flow cytometry.
- the adjustment window for the percentage of EGFP expression is larger than the three repeat fragments, and the plasmid 410 has the largest adjustment window for the percentage of EGFP expression, reaching 122.7.
- increasing the number of AP-1-REs will increase the regulatory window for the percentage of EGFP expression, that is, the window of plasmid 439 is 46.3, which is higher than that of plasmid 294 (the regulatory window is 18.8).
- the repeat fragments of HRE are increased, and the EGFP percentage regulation window is not higher than the regulation window of 3 HREs, that is, the EGFP percentage regulation window of plasmids 438-13 and 438-18 They are 1.6 and 2.1 respectively, both lower than or close to plasmid 263 (regulation window is 2.6).
- this example also uses plasmid 260 as the vector backbone, replacing CD20scFv with CD19scFv.
- plasmid 026 containing CD19 CAR as a template, design primers, and obtain CD19scFv by PCR.
- homologous recombination was used to homologate it to the BamHI/XhoI site of plasmid 260, and finally plasmid 292 containing CD19CAR was obtained. It was also transduced into Jurkat cells using the method of lentivirus, PMA/Iono was stimulated for 24h, and finally the EGFP expression was detected by flow cytometry.
- PBMC Human peripheral blood mononuclear cells
- T cells and B cells lymphocytes
- monocytes monocytes
- phagocytes dendritic cells
- a small number of cell types are an important cell component of the body's immune response function.
- PBMC is a research material often needed by researchers in the fields of immunology, antibody drug development, infectious diseases, hematological malignancies, vaccine development, and transplantation immunity.
- CAR-T therapy the final prepared CAR is also transduced into human PBMC through viruses and other methods.
- this example uses Ficoll reagent to separate PBMC to obtain T cells. Then use HEK293T cells to package the virus of plasmid 112, and use an ultrafiltration tube to concentrate the virus. Finally, the plasmid 112 was transduced into PBMC by way of virus, and the gene regulation of the combination of enhancer NFAT and IL-2TATA box in PBMC was further tested. effect.
- PBMC transduced with plasmid 112 when not stimulated, only 1.3% of the cells in the control group expressed EGFP.
- the expression of EGFP was as high as 62.6%, with a window of 48 times .
- CD3/CD28 Dynabeads activating TCR/costimulatory factor CD28
- PHA-P and Con A promoting mitosis
- CD3/CD28 Dynabeads stimulation EGFP expression increased significantly, reaching 40%, and the regulation window was 31 times.
- PHA-P and Con A stimulate the expression of plasmid 112 genes in a dose-dependent manner, and the 20 ⁇ g/ml PHA-P and 5 ⁇ g/ml Con A induction windows reached the maximum, 18.3% and 34.2%, respectively, but their maximum regulation The windows are lower than the induction windows of PMA/Iono and CD3/CD28. And when PHA-P and ConA were used at concentrations greater than or equal to 20 ⁇ g/ml and 5 ⁇ g/ml, the viability of PBMC cells decreased.
- CD3/CD28 Dynabeads, PHA-P, Con A and PMA/Iono all activate T cells.
- the enhancer NFAT and IL-2 TATA box can regulate the transcription and expression of the downstream gene EGFP.
- the windows for plasmid 112 to regulate gene expression are different.
- PMA/Iono has the best effect, with a window of 48 times. Therefore, the follow-up PBMC experiment also uses PMA/Iono as a stimulating factor to activate T cells.
- PMA/Iono stimulation was used to test the time node changes of plasmid 112 gene regulation in PBMC. Firstly, the plasmid 112 was transduced into PBMC through the concentrated lentivirus, and then PBMC was stimulated with PMA/Iono, and the PMA and ionomycin stimulation time exploration experiment was carried out.
- the experimental method is as follows:
- Inoculate 1.5 ⁇ 10 5 hPBMC cells in a 96-well plate the total volume of the medium is 200 ⁇ l, a total of 6 wells, respectively labeled AF.
- Add 1 ⁇ l DMSO to well A and add 10ng/ml PMA+1 ⁇ M ionomycin (total volume 1 ⁇ l) to the remaining wells.
- the supernatant was removed, and the cells were resuspended in 200 ⁇ l of fresh medium, and then inoculated in 96 wells to continue culturing. After 24h (calculated by adding PMA and ionomycin from the beginning), all the cells were collected, and the expression of EGFP on the cell surface was detected by flow cytometry.
- plasmid 260 NFAT-RE ⁇ NF- ⁇ B-RE
- plasmid 261 NF- ⁇ B-RE ⁇ NFAT-RE
- Plasmid 280 NFAT-RE ⁇ HRE-RE was transduced into PBMC through concentrated lentivirus, and then stimulated with PMA/Iono for 24h, and finally the expression of EGFP was detected by flow cytometry.
- the same method is used to test the regulation effect of the combination of other enhancers and IL-2 TATA box in PBMC.
- the plasmids 228 NFAT-RE
- 259 NF- ⁇ B-RE
- 281 HRE ⁇ NFAT-RE
- 294 AP-1-RE
- 407 NF- ⁇ B-RE ⁇ 7
- 410 NF- ⁇ B-RE ⁇ 6
- 437 11 NF- ⁇ B-RE
- 438-13 9 HRE
- 438-18 6 HRE
- 448 IFN- ⁇ enhancesome(2)
- the EGFP percentage adjustment window of plasmid 439 is the largest at 12 times
- the adjustment window of plasmid 281 is 10.2 times
- the adjustment window of plasmid 228 is 8 times
- the adjustment window of plasmid 448 is 7.6 times.
- the regulatory windows of plasmids 259 and 407 are both close to 2 times
- the regulatory windows of plasmids 437, 438-13 and 438-18 are the smallest.
- PBMC transduced with plasmid 260 and plasmid 292 after PMA/Iono stimulation EGFP expression increased significantly, and the regulatory window was 3.7 times and 5.7 times, respectively. This shows that CD19 CAR can also be regulated in PBMC.
- Raij B cells are used as target cells.
- Raji B cells are human lymphoma cells. Raji B cells are pre-labeled with PE-labeled anti-human CD20 flow cytometry antibody. As shown in Figure 8, almost 100% of Raji B cells express CD20 antigen on their surface, so Raji B cells can be used as Ideal target cells for in vitro antigen induction experiments.
- the antigen induction experiment requires that CAR-T cells are incubated with target cells expressing antigen to induce CAR expression.
- dyes are used to stain CAR-T cells.
- the adjustable CAR-T structure designed in the present disclosure uses EGFP to reflect the expression of CAR, due to CFSE and its fluorescein The excitation spectrum and emission spectrum of the analog are almost the same as EGFP, so CAR-T cells cannot be labeled with CFSE and its fluorescein analog dye.
- CytoTell TM Blue is used to label CAR-T cells.
- CytoTell TM Blue is a blue fluorescent dye that can uniformly stain cells. It is less cytotoxic and can be applied to EGFP-transduced cells.
- Plasmid 260 was transduced into PBMC by lentivirus to obtain CAR-T cells transduced with plasmid 260.
- the plasmid 260 has a CAR adjustable structure, namely NFAT-RE ⁇ NF- ⁇ B-RE and IL-2 TATA box The combination.
- Plasmid 245 was transduced into PBMC through lentivirus simultaneously to obtain CAR-T cells transduced with plasmid 245.
- Plasmid 245 contains a constitutive promoter EF1 ⁇ that regulates CAR expression. This constitutive promoter EF1 ⁇
- the CAR-T cell transduced with plasmid 245 is a CAR-T cell that does not have an adjustable structure for constitutive expression.
- CAR-T cells transduced with plasmid 245 can be used as control cells for CAR-T cells transduced with plasmid 260.
- the 260 T cells transduced with CytoTell TM Blue were respectively stained and incubated with Raji B cells at a ratio of 1:1.
- T cells stained with 260 were incubated with empty PBMCs that did not express CD20 antigen.
- Cells were collected at 24-48h, and the expression of EGFP in Cyto Tell TM Blue positive cell population was detected by flow cytometry.
- Figures 9A and 9B show the flow cytometry and data analysis results of antigen stimulation.
- this method compare the stimulation effects of antigen stimulation and the other two in vitro stimulation methods (CD3/CD28 and PMA/Iono).
- the percentage window of EGFP expression is close to 4 times, and after co-incubation with Raji B cells, the EGFP regulatory window is 3 times.
- the CAR-T transduced with plasmid 260 was incubated with PBMC or culture medium that did not express CD20 antigen, and the expression of EGFP was similar, which indicated that PBMC that did not express CD20 antigen had no stimulating effect on CAR-T.
- the CAR-T cell transduced with plasmid 245 was used as a control. When it was cultured in medium, the expression of EGFP was 3.3%. After co-incubation with Raji B cells, the expression of EGFP was 3.7%. This indicates that the expression of plasmid 245 is Structure has no regulatory effect in PBMC.
- CARs with different enhancer and IL-2 TATA box combinations can be activated after recognizing tumor antigens, and then regulate their own EGFP expression, with a window of 1.4 times to 8.5 times .
- Plasmid 228, that is, NFAT-RE has the strongest regulatory effect, with a window of 8.5 times, while plasmid 259, that is, NF- ⁇ B-RE has the smallest regulatory window, which is 1.4 times. This may be related to the high background in PBMC after its transduction. Value related.
- the regulated CAR can still be activated by PMA/Iono stimulation.
- This article uses the same method to test its antigen stimulation effect.
- Raji B is a lymphoblast-like cell line cultured in vitro.
- CD20 protein on the cell surface, it also highly expresses CD19 protein. Therefore, it can be used as a target cell for CD19 CAR-T.
- This example is based on the combination of NFAT-RE ⁇ NF- ⁇ B-RE and IL-2 TATA box to explore the antigen induction of CD19 CAR.
- NFAT-RE SEQ ID NO: 15
- IL-2 TATA box was constructed on the retroviral vector-plasmid 169, and plasmid 417 was obtained.
- the retrovirus was packaged by the cell line D4, then the plasmid 417 was transduced into Jurkat cells by the retrovirus, and finally stimulated with PMA/Iono.
- the present disclosure also constructs the structure of the enhancer response element on 410 and the CAR through the method of homologous recombination on the retroviral vector-plasmid 169, to obtain plasmid 440.
- the retrovirus was packaged with the cell line D4, and then the plasmid 440 was transduced into Jurkat cells by the retrovirus, and finally stimulated with PMA/Iono.
- the expression of EGFP in Jurkat cells transduced with plasmid 440 increased from 0.01% to 3.3%, with a window of 330 times.
- PMA/Iono stimulation the MFI of EGFP also increases, which shows that the regulatory structure designed in this embodiment can also regulate the expression of CAR on the retroviral vector.
- the adjustable CAR that combines different enhancers and IL-2 TATA boxes designed in this embodiment is suitable for different tumor targets. Once CAR-T comes into contact with the antigen, it will be quickly activated to regulate the expression of its own CAR.
- Such an adjustable structure can become another new way to treat tumors, including solid tumors.
- the ONE-Glo TM Luciferase Assay System is used to detect the tumor-killing effect of the adjustable CAR-T, and the specific method is as follows:
- the plasmid 056 was transduced into K562 cells by lentivirus, and the CD20 expression of K562 cells was detected by flow cytometry 72 hours later. Then the cell suspension is prepared, that is, 100 K562/056 polyclonal cells are added to 10ml of medium containing 8 ⁇ g/ml puromycin, and after mixing, they are inoculated in a 96-well plate with 100 ⁇ l of medium per well. After 10-15 days, select monoclonal cells, expand the culture, and finally detect the expression of CD20 expressed by K562 cells by flow cytometry, and then K562/056 cell line can be obtained. Then the K562/056/099 cell line was constructed on the basis of the K562/056 cell line.
- lentivirus was used to transduce plasmid 099 into K562/056 cell line. After 72 hours, the expression of EGFP on the cell surface was detected by flow cytometry.
- the method for preparing cell suspension is the same as the construction of K562/056 cell line. After 10-15 days, select monoclonal cells and expand the culture, and finally detect the expression of EGFP on the cell surface by flow cytometry. The K562/056/099 cell line can be obtained.
- Inoculate 2 ⁇ 10 4 effector cells that is, PBMC cells expressing CAR in a 384-well plate, and then inoculate target cells expressing the corresponding antigen and Luciferase at the same time according to the experimental requirements.
- the total culture system is 80 ⁇ l, and the control group is no
- the CAR-expressing effector cells are incubated with the same target cells. Place the 384-well plate in a 37°C, 5% CO 2 incubator for culture.
- K562/056/099 cells construct K562/056/099 cells, a stable cell line expressing both human CD20 antigen and firefly luciferase in K562 cells, and then transduce plasmid 260 into PBMC by lentivirus, as a control, synchronously transduce ⁇ Plasmid 245. Then the expression of CAR in PBMC was detected by flow cytometry. As shown in FIG. 12A, plasmid 245 and plasmid 260 were transduced into PBMC, and their CAR expression was 11% on the 15th and 18th days, and then the 15th and 18th day PBMC were used for the killing experiment.
- the CAR-expressing PBMC and the target cell K562/056/099 were incubated at a ratio of 1:1, 3:1, or 10:1. After 24 hours, the tumor killing was detected using Promega's Luciferase detection kit. As shown in Figure 12B, when the effector cell PBMC (Effector) and the target cell K562/056/099 are incubated at a ratio of 1:1, the PBMC transduced with plasmid 245 and plasmid 260 can both kill the tumor, with a killing ratio of 50 respectively. % And 62%. With the increase in the number of PBMC, the better the killing effect.
- the killing rate of PBMC transduced with plasmid 245 is 92.5%, while that of plasmid 260 is 99.5%.
- Plasmid 245 and plasmid 260 are CAR in PBMC The expression of both is 11%, but the killing effect of plasmid 260 is better than that of plasmid 245, which shows that the killing effect of the adjustable CAR with the NFAT-RENF- ⁇ B-RE-IL-2 TATA box structure is better than the traditional non-adjustable CAR is good.
- Cytokine is a low molecular weight soluble protein produced by immunogens, mitogens or other factors that stimulate cells, such as interleukin 2 (IL-2) and interferon IFN- ⁇ , which can regulate innate immunity and adaptability. Immune response, promotion of hematopoiesis, and stimulation of cell activation, proliferation and differentiation.
- IL-2 is a cytokine of the chemokine family, which is mainly synthesized by T cells (especially CD4 + T cells) after being stimulated by antigens or mitotic sources, and plays an important role in the body's immune response and anti-viral infection.
- IFN- ⁇ belongs to type II interferon. It is an important immune regulatory factor in the body.
- CTL Cytotoxic lymphocyte
- the adjustable CAR designed in this example has a powerful tumor-killing effect, and compared to the CAR expression driven by the EF-1 ⁇ promoter (that is, the CAR non-regulated promoter), this adjustable CAR CAR has better killing effect in PBMC.
- This example investigates the regulation of the combination of different enhancer response elements and promoters in mouse spleen cells (SPL).
- SPL mouse spleen cells
- plasmid 417 containing the NFAF enhancer, whose nucleotide sequence is shown in SEQ ID NO: 15
- plasmid 440 containing the NF- ⁇ B enhancer, whose nucleotide sequence is shown in SEQ ID NO: : 119
- the retrovirus was packaged by cell line 6#, and then the plasmids 417 and 440 were transduced into SPL by the retrovirus.
- PMA/Iono were used to stimulate the mouse spleen cells (SPL) transduced with these two plasmids respectively. It can be seen from Fig.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
质粒Plasmid | 引物序列(SEQ ID NO:)Primer sequence (SEQ ID NO:) |
241241 | 24、3524, 35 |
242242 | 36、3736, 37 |
243-1243-1 | 38、39、40、41、42、4338, 39, 40, 41, 42, 43 |
243-5243-5 | 38、39、40、41、42、4338, 39, 40, 41, 42, 43 |
244244 | 44、45、46、4744, 45, 46, 47 |
262262 | 48、49、50、5148, 49, 50, 51 |
293293 | 52、5352, 53 |
445445 | 54、5554, 55 |
446446 | 56、5756, 57 |
459459 | 58、59、60、6158, 59, 60, 61 |
460460 | 61、62、63、6461, 62, 63, 64 |
质粒Plasmid | PCR模板PCR template | 引物(SEQ ID NO:)Primer (SEQ ID NO:) | 酶切质粒Restriction digestion plasmid | 限制性内切酶Restriction endonuclease |
228228 | 112112 | 65、6665, 66 | 245245 | Spel和8amHISpel and 8amHI |
259259 | 241241 | 66、6766, 67 | 245245 |
Spel和BamHISpel and |
260260 | 241241 | 68、6968, 69 | 228228 |
EcoRV |
261261 | 228228 | 68、6968, 69 | 259259 | EcoRVEcoRV |
263263 | 262262 | 66、7066, 70 | 245245 |
Spel和8amHISpel and |
280280 | 262262 | 68、7168, 71 | 228228 | EcoRVEcoRV |
281281 | 112112 | 68、7268, 72 | 263263 |
EcoRV |
292292 | 026026 | 73、7473, 74 | 260260 | Xhol和8amHIXhol and 8amHI |
294294 | 293293 | 65、7065, 70 | 245245 | Spel和BamHISpel and BamHI |
407407 | // | 75、7675, 76 | 259259 | EcoRVEcoRV |
410410 | // | 77、7877, 78 | 259259 | EcoRVEcoRV |
437437 | // | 77、7877, 78 | 410410 | EcoRVEcoRV |
438-13438-13 | 263263 | 79、8079, 80 | 263263 | SpelSpel |
438-18438-18 | 263263 | 79、8079, 80 | 263263 | SpelSpel |
439439 | // | 81、8281, 82 | 294294 | EcoRVEcoRV |
448448 | 446446 | 60、6860, 68 | 245245 | Spel和BamHISpel and BamHI |
408408 | // | 83、84、85、8683, 84, 85, 86 | 169169 |
Xhol和SalIXhol and |
417417 | 112112 | 87、8887, 88 | 408408 |
SalI |
440440 | 410410 | 89、90、91、9289, 90, 91, 92 | 417417 | HindIII/BamHIHindIII/BamHI |
Claims (10)
- 一种肿瘤抗原诱导的基因表达自我调节核苷酸序列,所述序列包含:A tumor antigen-induced gene expression self-regulating nucleotide sequence, the sequence comprising:(1)启动子序列,和(1) Promoter sequence, and(2)增强子序列,(2) Enhancer sequence,优选地,所述启动子选自起始子、TATA盒和/或其它核心启动子元件,所述其它核心启动子元件选自以下元件:BREu(upstream TFⅡB Recognition Element)、MTE(Motif Ten Element)、DPE(Downstream Promoter Element)、DCE(Downstream Core Element)、XCPE1(X Core Promoter Element 1)等;Preferably, the promoter is selected from an initiator, a TATA box and/or other core promoter elements, and the other core promoter elements are selected from the following elements: BREu (upstream TFIIB Recognition Element), MTE (Motif Ten Element) , DPE (Downstream Promoter Element), DCE (Downstream Core Element), XCPE1 (X Core Promoter Element 1), etc.;优选地,所述TATA盒是IL-2 TATA盒;Preferably, the TATA box is an IL-2 TATA box;优选地,所述增强子选自以下反应元件:活化T细胞核因子反应元件(NFAT-RE)、核因子κB反应元件(NF-κB-RE)、T细胞因子/淋巴增强因子反应元件(TCF-RE)、激活蛋白-1反应元件(AP-1-RE)、缺氧诱导因子反应元件(HRE)、FoxO转录因子反应元件(FoxO-RE);Preferably, the enhancer is selected from the following response elements: activated T cell nuclear factor response element (NFAT-RE), nuclear factor κB response element (NF-κB-RE), T cell factor/lymph enhancer factor response element (TCF- RE), Activin-1 Response Element (AP-1-RE), Hypoxia Inducible Factor Response Element (HRE), FoxO Transcription Factor Response Element (FoxO-RE);优选地,所述肿瘤抗原是肿瘤细胞表面的肿瘤相关抗原。Preferably, the tumor antigen is a tumor-associated antigen on the surface of tumor cells.
- 根据权利要求1所述肿瘤抗原诱导的基因表达自我调节核苷酸序列,其中,所述增强子为单拷贝增强子、多拷贝增强子或者不同增强子的组合;The tumor antigen-induced gene expression self-regulating nucleotide sequence according to claim 1, wherein the enhancer is a single-copy enhancer, a multi-copy enhancer, or a combination of different enhancers;优选地,所述序列与下述序列具有至少60%、65%、70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、99.5%或99.9%同一性:SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:3、SEQ ID NO:4、SEQ ID NO:5、SEQ ID NO:6、SEQ ID NO:7、SEQ ID NO:8、SEQ ID NO:9、SEQ ID NO:10、SEQ ID NO:11、SEQ ID NO:12、SEQ ID NO:13、SEQ ID NO:14、SEQ ID NO:15、SEQ ID NO:16、SEQ ID NO:17、SEQ ID NO:18、SEQ ID NO:19、SEQ ID NO:20、SEQ ID NO:21、SEQ ID NO:22、SEQ ID NO:23、SEQ ID NO:24、SEQ ID NO:119、SEQ ID NO:120、SEQ ID NO:121、SEQ ID NO:122、SEQ ID NO:123、SEQ ID NO:124、SEQ ID:128;Preferably, the sequence and the following sequence have at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% , 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identity: SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10. SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID: 128;优选地,所述增强子单拷贝的核苷酸序列选自以下序列:SEQ ID NO:120、SEQ ID NO:121、SEQ ID NO:122、SEQ ID NO:123、SEQ ID NO:124、SEQ ID NO:125、SEQ ID:128;Preferably, the nucleotide sequence of the single copy of the enhancer is selected from the following sequences: SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID: 128;优选地,所述多拷贝为重复2-20次拷贝;尤其优选地,所述多拷贝为重复2-9次或重复2-7次拷贝;更优选地,所述多拷贝为重复5-6次拷贝;Preferably, the multiple copies are repeated 2-20 times; especially preferably, the multiple copies are repeated 2-9 times or repeated 2-7 times; more preferably, the multiple copies are repeated 5-6 times. Copy优选地,所述增强子多拷贝反应元件的核苷酸序列选自以下序列:SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:3、SEQ ID NO:4、SEQ ID NO:5、SEQ ID NO:6、SEQ ID NO:7、SEQ ID NO:8、SEQ ID NO:9、SEQ ID NO:10、SEQ ID NO:11、SEQ ID NO:12、SEQ ID NO:13、SEQ ID NO:14;Preferably, the nucleotide sequence of the enhancer multi-copy response element is selected from the following sequences: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 , SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14;优选地,所述增强子单拷贝的反向核苷酸序列为SEQ ID NO:126或SEQ ID NO:127;Preferably, the reverse nucleotide sequence of the single copy of the enhancer is SEQ ID NO: 126 or SEQ ID NO: 127;优选地,所述增强子多拷贝的反向核苷酸序列为SEQ ID NO:15或SEQ ID NO:119;Preferably, the reverse nucleotide sequence of the multiple copies of the enhancer is SEQ ID NO: 15 or SEQ ID NO: 119;优选地,所述不同增强子的组合反应元件的核苷酸序列选自以下序列:SEQ ID NO:17、SEQ ID NO:18、SEQ ID NO:19、SEQ ID NO:20、SEQ ID NO:21、SEQ ID NO:22、SEQ ID NO:23和SEQ ID NO:24;Preferably, the nucleotide sequence of the combined response element of the different enhancers is selected from the following sequences: SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21. SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24;优选地,所述启动子的核苷酸序列为SEQ ID NO:16。Preferably, the nucleotide sequence of the promoter is SEQ ID NO: 16.
- 一种核酸构建体,其包含权利要求1或2所述的肿瘤抗原诱导的基因表达自我调节核苷酸序列和编码能与肿瘤抗原特异性结合的蛋白的核苷酸序列;优选地,所述肿瘤抗原是肿瘤细胞表面的肿瘤相关抗原;A nucleic acid construct comprising the tumor antigen-induced gene expression self-regulating nucleotide sequence of claim 1 or 2 and a nucleotide sequence encoding a protein capable of specifically binding to tumor antigens; preferably, said Tumor antigens are tumor-associated antigens on the surface of tumor cells;优选地,所述能与肿瘤抗原特异性结合的蛋白选自:单链抗体(ScFv)、受体、配体、蛋白支架和/或其它嵌合抗原受体(CAR);优选地,所述蛋白支架选自Affibody、DARPin、单体(Monobody)、Anticalin4;优选地,所述单体为Centyrin;更优选地,所述能与肿瘤抗原特异性结合的蛋白为嵌合抗原受体(CAR);Preferably, the protein that can specifically bind to tumor antigens is selected from the group consisting of single-chain antibodies (ScFv), receptors, ligands, protein scaffolds and/or other chimeric antigen receptors (CAR); preferably, the The protein scaffold is selected from Affibody, DARPin, Monobody, Anticalin4; preferably, the monomer is Centyrin; more preferably, the protein that can specifically bind to tumor antigens is a chimeric antigen receptor (CAR) ;优选地,所述嵌合抗原受体(CAR)包含肿瘤相关抗原结合结构域、跨膜结构域和信号转导结构域;优选地,所述嵌合抗原受体(CAR)的氨基酸序列为SEQ ID NO:26或SEQ ID NO:28;Preferably, the chimeric antigen receptor (CAR) comprises a tumor-associated antigen binding domain, a transmembrane domain and a signal transduction domain; preferably, the amino acid sequence of the chimeric antigen receptor (CAR) is SEQ ID NO: 26 or SEQ ID NO: 28;优选地,编码所述嵌合抗原受体(CAR)的核苷酸序列与下述序列具有至少60%、65%、70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、99.5%或99.9%同一性:SEQ ID NO:25、SEQ ID NO:27、SEQ ID NO:93、SEQ ID NO:94、SEQ ID NO:95、SEQ ID NO:96、SEQ ID NO:97、SEQ ID NO:98、SEQ ID NO:99、SEQ ID NO:100、SEQ ID NO:101、SEQ ID NO:102、SEQ ID NO:103、SEQ ID NO:104、SEQ ID NO:105、SEQ ID NO:106、SEQ ID NO:107、SEQ ID NO:108和SEQ ID NO:109;Preferably, the nucleotide sequence encoding the chimeric antigen receptor (CAR) has at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84 %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identity: SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO :98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106 , SEQ ID NO: 107, SEQ ID NO: 108 and SEQ ID NO: 109;优选地,编码所述嵌合抗原受体(CAR)的核苷酸序列为SEQ ID NO:25或SEQ ID NO:27;Preferably, the nucleotide sequence encoding the chimeric antigen receptor (CAR) is SEQ ID NO: 25 or SEQ ID NO: 27;优选地,编码所述嵌合抗原受体(CAR)的核苷酸序列选自SEQ ID NO:93、SEQ ID NO:94、SEQ ID NO:95、SEQ ID NO:96、SEQ ID NO:97、SEQ ID NO:98、SEQ ID NO:99、SEQ ID NO:100、SEQ ID NO:101、SEQ ID NO:102、SEQ ID NO:103、SEQ ID NO:104、SEQ ID NO:105、SEQ ID NO:106、SEQ ID NO:107、SEQ ID NO:108和SEQ ID NO:109。Preferably, the nucleotide sequence encoding the chimeric antigen receptor (CAR) is selected from SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97 , SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, and SEQ ID NO: 109.
- 权利要求3所述的核酸构建体,其为粘粒、质粒或病毒载体或非病毒载体;The nucleic acid construct of claim 3, which is a cosmid, a plasmid, a viral vector or a non-viral vector;优选地,所述病毒载体选自慢病毒载体、逆转录病毒载体、腺病毒载体、腺相关病毒载体;Preferably, the viral vector is selected from a lentiviral vector, a retroviral vector, an adenovirus vector, and an adeno-associated virus vector;优选地,所述非病毒载体选自睡美人质粒转座***、PiggyBac***或微环DNA;Preferably, the non-viral vector is selected from Sleeping Beauty plasmid transposition system, PiggyBac system or minicircle DNA;优选地,所述核酸构建体的核酸序列选自:SEQ ID NO:110、SEQ ID NO:111、SEQ ID NO:112、SEQ ID NO:113、SEQ ID NO:114、SEQ ID NO:115、SEQ ID NO:116和SEQ ID NO:117;或者,所述核酸构建体的核酸序列具有与 上述核苷酸序列具有至少60%、65%、70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、99.5%或99.9%同一性。Preferably, the nucleic acid sequence of the nucleic acid construct is selected from: SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116 and SEQ ID NO: 117; or, the nucleic acid sequence of the nucleic acid construct has at least 60%, 65%, 70%, 75%, 80%, 81%, 82% of the above-mentioned nucleotide sequence. %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identity.
- 权利要求1或2所述的肿瘤抗原诱导的基因表达自我调节核苷酸序列和/或权利要求3或4所述的核酸构建体用于制备针对肿瘤相关抗原的基因修饰的免疫细胞。The tumor antigen-induced gene expression self-regulating nucleotide sequence of claim 1 or 2 and/or the nucleic acid construct of claim 3 or 4 are used to prepare genetically modified immune cells against tumor-associated antigens.
- 分离的宿主细胞,其包含权利要求1或2所述的肿瘤抗原诱导的基因表达自我调节核苷酸序列和/或权利要求3或4所述的核酸构建体;优选地,所述宿主细胞为哺乳动物细胞;更优选地,所述宿主细胞为PBMC、T细胞、NK细胞、NKT细胞、巨噬细胞或细胞系;优选地,所述宿主细胞选自HEK293、HEK293-T或Jurkat;An isolated host cell comprising the tumor antigen-induced gene expression self-regulating nucleotide sequence of claim 1 or 2 and/or the nucleic acid construct of claim 3 or 4; preferably, the host cell is Mammalian cells; more preferably, the host cells are PBMC, T cells, NK cells, NKT cells, macrophages or cell lines; preferably, the host cells are selected from HEK293, HEK293-T or Jurkat;优选地,所述宿主细胞还表达其他序列,所述其他序列包括细胞因子、另一种CAR、趋化因子受体、降低PD-1表达的siRNA或者阻断PD-L1的蛋白、TCR、或安全开关;Preferably, the host cell also expresses other sequences, and the other sequences include cytokine, another CAR, chemokine receptor, siRNA that reduces PD-1 expression, or protein that blocks PD-L1, TCR, or Safety switch;优选地,所述的细胞因子选自IL-12、IL-15、IL-21、或I型干扰素;Preferably, the cytokine is selected from IL-12, IL-15, IL-21, or type I interferon;优选地,所述趋化因子受体选自CCR2、CCR5、CXCR3;Preferably, the chemokine receptor is selected from CCR2, CCR5, CXCR3;优选地,所述安全开关选自iCaspase-9、Truncated EGFR。Preferably, the safety switch is selected from iCaspase-9, Truncated EGFR.
- 药物组合物,其包含权利要求1或2所述的肿瘤抗原诱导的基因表达自我调节核苷酸序列、权利要求3或4所述的核酸构建体和/或权利要求6所述的宿主细胞,以及药学上可接受的载体。A pharmaceutical composition comprising the tumor antigen-induced gene expression self-regulating nucleotide sequence of claim 1 or 2, the nucleic acid construct of claim 3 or 4, and/or the host cell of claim 6, And a pharmaceutically acceptable carrier.
- 权利要求1或2所述的肿瘤抗原诱导的基因表达自我调节核苷酸序列、权利要求3或4所述的核酸构建体、权利要求6所述的宿主细胞和/或权利要求7所述的药物组合物在制备药物中的用途;The tumor antigen-induced gene expression self-regulating nucleotide sequence of claim 1 or 2, the nucleic acid construct of claim 3 or 4, the host cell of claim 6 and/or the nucleotide sequence of claim 7 The use of the pharmaceutical composition in the preparation of medicines;优选地,所述药物用于诊断、治疗或预防癌症、炎性疾病、自身免疫性疾病中的一种或多种;Preferably, the medicine is used to diagnose, treat or prevent one or more of cancer, inflammatory disease, and autoimmune disease;优选地,所述药物用于诊断、治疗或预防肿瘤,优选地,所述肿瘤选自血液癌和实体瘤;更优选地,所述药物用于诊断、治疗或预防的血液癌选自白血病、淋巴瘤、骨髓瘤的一种或多种;更优选地,所述药物用于诊断、治疗或预防的实体瘤选自肺癌、肝癌、食道癌胰腺癌、卵巢癌、肾癌、膀胱癌、胰腺癌、胃癌、肠癌、***癌中的一种或多种。Preferably, the drug is used to diagnose, treat or prevent tumors. Preferably, the tumors are selected from blood cancers and solid tumors; more preferably, the blood cancers used for the diagnosis, treatment or prevention of the drugs are selected from leukemia, One or more of lymphoma and myeloma; more preferably, the solid tumor used by the drug for diagnosis, treatment or prevention is selected from lung cancer, liver cancer, esophageal cancer, pancreatic cancer, ovarian cancer, kidney cancer, bladder cancer, pancreas One or more of cancer, stomach cancer, bowel cancer, and prostate cancer.
- 一种CAR-T或TCR-T细胞的制备方法,所述方法包括以下步骤:A method for preparing CAR-T or TCR-T cells, the method comprising the following steps:(1)构建表达自我诱导型CAR或工程化TCR的核酸构建体,所述核酸构建体包含权利要求1或2所述的肿瘤抗原诱导的基因表达自我调节核苷酸序列和编码能与肿瘤抗原特异性结合的蛋白的核苷酸序列;优选地,所述核酸构建体选自粘粒、质粒、病毒载体或非病毒载体;优选地,所述病毒载体选自慢病毒载体、逆转录病毒载体、腺病毒载体、腺相关病毒载体;优选地,所述非病毒载体选自睡美人质粒转座***、PiggyBac***或微环DNA;优选地,采用包装细胞系包装所述病毒;(1) Construction of a nucleic acid construct expressing a self-inducible CAR or engineered TCR, the nucleic acid construct comprising the tumor antigen-induced gene expression self-regulating nucleotide sequence of claim 1 or 2 and a nucleotide sequence encoding a tumor antigen The nucleotide sequence of the protein that specifically binds; preferably, the nucleic acid construct is selected from a cosmid, a plasmid, a viral vector or a non-viral vector; preferably, the viral vector is selected from a lentiviral vector, a retroviral vector, Adenovirus vector, adeno-associated virus vector; preferably, the non-viral vector is selected from Sleeping Beauty plasmid transposition system, PiggyBac system or minicircle DNA; preferably, packaging cell line is used to package the virus;(2)分离外周血单个核细胞,得到T淋巴细胞;(2) Isolate peripheral blood mononuclear cells to obtain T lymphocytes;(3)将步骤(1)所述的核酸构建体转导到步骤(2)所述的T淋巴细胞中,得到包含所述构建体的T淋巴细胞;优选地;将病毒载体或者非病毒载体转导到T淋巴细胞中;(3) Transducing the nucleic acid construct described in step (1) into the T lymphocytes described in step (2) to obtain T lymphocytes containing the construct; preferably; a viral vector or a non-viral vector Transduction into T lymphocytes;(4)将步骤(3)中得到的包含所述构建体的T淋巴细胞扩大培养,即可得到CAR-T或TCR-T细胞。(4) Expand the culture of the T lymphocytes containing the construct obtained in step (3) to obtain CAR-T or TCR-T cells.
- 一种治疗受试者中的与肿瘤相关抗原相关的疾病的方法,其包括向所述受试者施用权利要求3或4所述的核酸构建体、权利要求6所述的宿主细胞和/或权利要求7所述的药物组合物;优选地,所述受试者是哺乳动物;更优选地,所述受试者是人。A method for treating a tumor-associated antigen-related disease in a subject, which comprises administering to the subject the nucleic acid construct according to claim 3 or 4, the host cell according to claim 6, and/or The pharmaceutical composition of claim 7; preferably, the subject is a mammal; more preferably, the subject is a human.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010592743.8 | 2020-06-24 | ||
CN202010592743 | 2020-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021259334A1 true WO2021259334A1 (en) | 2021-12-30 |
Family
ID=79282006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/101900 WO2021259334A1 (en) | 2020-06-24 | 2021-06-23 | Self-regulating chimeric antigen receptor and application thereof in tumor immunity |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021259334A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111315402A (en) * | 2017-08-15 | 2020-06-19 | 艾达普特免疫有限公司 | T cell modification |
WO2023010038A1 (en) * | 2021-07-29 | 2023-02-02 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Synthetic nucleic acid elements for enhancing car t cell efficacy |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040214757A1 (en) * | 1986-01-09 | 2004-10-28 | David Baltimore | Nuclear factors associated with transcriptional regulation |
CN110913871A (en) * | 2017-05-17 | 2020-03-24 | 西雅图儿童医院(Dba西雅图儿童研究所) | Generation of mammalian T cell activation-inducible synthetic promoters (SYN + PRO) to improve T cell therapy |
WO2020118634A1 (en) * | 2018-12-13 | 2020-06-18 | 科济生物医药(上海)有限公司 | Immune effector cell targeting gpc3 and application thereof |
CN111315402A (en) * | 2017-08-15 | 2020-06-19 | 艾达普特免疫有限公司 | T cell modification |
-
2021
- 2021-06-23 WO PCT/CN2021/101900 patent/WO2021259334A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040214757A1 (en) * | 1986-01-09 | 2004-10-28 | David Baltimore | Nuclear factors associated with transcriptional regulation |
CN110913871A (en) * | 2017-05-17 | 2020-03-24 | 西雅图儿童医院(Dba西雅图儿童研究所) | Generation of mammalian T cell activation-inducible synthetic promoters (SYN + PRO) to improve T cell therapy |
CN111315402A (en) * | 2017-08-15 | 2020-06-19 | 艾达普特免疫有限公司 | T cell modification |
WO2020118634A1 (en) * | 2018-12-13 | 2020-06-18 | 科济生物医药(上海)有限公司 | Immune effector cell targeting gpc3 and application thereof |
Non-Patent Citations (2)
Title |
---|
KATHARINA ZIMMERMANN, JOHANNES KUEHLE, ANNA CHRISTINA DRAGON, MELANIE GALLA, CHRISTINA KLOTH, LOREEN SOPHIE RUDEK, I. EROL SANDALC: "Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines", CANCERS, vol. 12, no. 2, pages 375, XP055727985, DOI: 10.3390/cancers12020375 * |
KULEMZIN SERGEY V., MATVIENKO DARIA A., SABIROV ARTUR H., SOKRATYAN ARPINE M., CHERNIKOVA DARIA S., BELOVEZHETS TATYANA N., CHIKAE: "Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines", BMC MEDICAL GENOMICS, vol. 12, no. S2, 1 March 2019 (2019-03-01), pages 20 - 25, XP055833898, DOI: 10.1186/s12920-019-0489-4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111315402A (en) * | 2017-08-15 | 2020-06-19 | 艾达普特免疫有限公司 | T cell modification |
CN111315402B (en) * | 2017-08-15 | 2024-05-07 | 艾达普特免疫有限公司 | T cell modification |
WO2023010038A1 (en) * | 2021-07-29 | 2023-02-02 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Synthetic nucleic acid elements for enhancing car t cell efficacy |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7008350B2 (en) | CAR expression vector and CAR expression T cells | |
AU2016238963B2 (en) | Method and compositions for cellular immunotherapy | |
RU2716716C2 (en) | Compositions and methods for boosting the effectiveness of adoptive cell immunotherapy | |
JP6971986B2 (en) | Mesenchymal stem cells to enhance the antitumor activity of immunotherapy | |
JP2021516256A (en) | CD19-based chimeric antigen receptor and its utilization | |
US20210155702A1 (en) | Antibody-modified chimeric antigen receptor modified t cell and uses thereof | |
JP7475088B2 (en) | Immunocompetent cells expressing cell surface molecules that specifically recognize human mesothelin, IL-7, and CCL19 | |
WO2022007795A1 (en) | Chimeric antigen receptor and use thereof | |
WO2022007804A1 (en) | T lymphocyte and use thereof | |
TW202016295A (en) | Car-expressing t cells and car expression vector | |
CN112204133B (en) | CAR NK cells | |
JP2021525101A (en) | Modified anti-CD19 CAR-T cells | |
WO2021259334A1 (en) | Self-regulating chimeric antigen receptor and application thereof in tumor immunity | |
US20230000918A1 (en) | Chimeric antigen receptors, compositions and applications thereof | |
WO2021136538A1 (en) | Enhanced cart cell promoting solid tumor infiltration, preparation method therefor, and cell medication thereof | |
JP2022522786A (en) | Constructively active chimeric cytokine receptor | |
JP2021517450A (en) | Chimeric antigen receptor that binds to SSEA4 and its use | |
JP2023524873A (en) | Method | |
JP2021509290A (en) | Bidirectionally activated co-stimulating molecular receptors and their uses | |
CN111378046B (en) | Immune effector cell conversion receptor | |
CN111983218A (en) | Kit for detecting interaction of living cell-living cell surface receptor-ligand | |
US11359012B1 (en) | Specific chimeric antigen receptor cells targeting human CLDN18A2, preparation method and application thereof | |
WO2021093818A1 (en) | Tmem59 protein dimer or chimeric expression receptor improving t cell function | |
US11364267B1 (en) | Bi-specific targeting human NKG2DL and CLDN18A2 chimeric antigen receptor cells, preparation method and application thereof | |
WO2024066026A1 (en) | OPTIMIZED CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 AND USE THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21828756 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21828756 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21828756 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 04.07.2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21828756 Country of ref document: EP Kind code of ref document: A1 |